Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 2 | Archives of Public Health

Fig. 2

From: Evaluating anti-MRSA antibiotic stewardship with a focus on trends in consumption and resistance in a tertiary hospital in Alexandria, Egypt from 2019 to 2023

Fig. 2

Segmented Quarterly Trends in Hospital Consumption of Linezolid and Combined Vancomycin/Teicoplanin Before and After the COVID-19 Pandemic in a Tertiary Hospital in Alexandria, Egypt from 2019 to 2023. This figure presents a segmented regression analysis of quarterly hospital consumption trends of Linezolid (top panel) and combined Vancomycin/Teicoplanin (bottom panel) before and after the onset of the COVID-19 pandemic in a tertiary hospital in Alexandria, Egypt. Vertical lines indicate the start of COVID-19 case admissions. Abbreviations: DDD/1000PD, defined daily doses per 1000 patient-days; β, regression coefficient

Back to article page

Archives of Public Health

ISSN: 2049-3258